Narcolepsy - Pipeline Review, H1 2018

Date: April 10, 2018
Pages: 80
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: NF8C48075DAEN
Leaflet:

Download PDF Leaflet

Narcolepsy - Pipeline Review, H1 2018
Narcolepsy - Pipeline Review, H1 2018

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Narcolepsy - Pipeline Review, H1 2018, provides an overview of the Narcolepsy (Central Nervous System) pipeline landscape.

Narcolepsy is a sleep disorder that causes excessive sleepiness and frequent daytime sleep attacks. Symptoms of narcolepsy include excessive daytime sleepiness (EDS), cataplexy, hallucinations and sleep paralysis. Narcolepsy treatment includes lifestyle change, medication and counseling.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Narcolepsy - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Narcolepsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Narcolepsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Narcolepsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 6, 3, 3, 4, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Narcolepsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Narcolepsy (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Narcolepsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Narcolepsy (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Narcolepsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Narcolepsy (Central Nervous System)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Narcolepsy (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Narcolepsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


NOTE: Out of security concerns Global Markets Direct requires using corporate email address.
Introduction
Global Markets Direct Report Coverage
Narcolepsy - Overview
Narcolepsy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Narcolepsy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Narcolepsy - Companies Involved in Therapeutics Development
Avadel Pharmaceuticals Plc
Bioprojet SCR
Evotec AG
F. Hoffmann-La Roche Ltd
H.A.C. Pharma
Heptares Therapeutics Ltd
Jazz Pharmaceuticals Plc
Ono Pharmaceutical Co Ltd
OptiNose US Inc
Reset Therapeutics Inc
SK Biopharmaceuticals Co Ltd
Taisho Pharmaceutical Holdings Co Ltd
Takeda Pharmaceutical Co Ltd
Theranexus SAS
Narcolepsy - Drug Profiles
(flecainide acetate + modafinil) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
arbaclofen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JZP-258 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JZP-386 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JZP-507 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LGD-3437 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mazindol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mazindol CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONO-4127 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OPN-021 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pentylenetetrazol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pitolisant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RO-5256390 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Orexin Receptor 2 for Narcolepsy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Orexin-2 for Narcolepsy and Sleep Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize Orexin Receptor for Narcolepsy and Sleep Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sodium oxybate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sodium oxybate ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
solriamfetol hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-925 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TS-091 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XW-10172 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YNT-185 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Narcolepsy - Dormant Projects
Narcolepsy - Discontinued Products
Narcolepsy - Product Development Milestones
Featured News & Press Releases
Mar 12, 2018: XW Labs Initiates First-in-Human Phase I Study for Novel Narcolepsy Treatment
Mar 02, 2018: Jazz Pharmaceuticals Announces FDA Acceptance of NDA for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
Jan 11, 2018: Theranexus announces issuance of European patent covering its drug candidate THN102 for treatment of narcolepsy and Parkinson’s disease
Jan 10, 2018: Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for FT 218 for the Treatment of Narcolepsy
Dec 21, 2017: Jazz Pharma Submits NDA for Solriamfetol (JZP-110) for Excessive Sleepiness Associated With Narcolepsy and Obstructive Sleep Apnea
Jun 06, 2017: Jazz Pharmaceuticals Presents Data for the Phase 3 TONES 2 Study of JZP-110 in Patients with Excessive Sleepiness Associated with Narcolepsy
May 24, 2017: Jazz Pharma to Present Phase 2/3 Data on Investigational use of Sodium Oxybate During 31st Annual SLEEP Meeting
May 24, 2017: Jazz Pharmaceuticals Announces Webcast Discussion of Data of Xyrem to be Presented at APSS
May 24, 2017: Jazz Pharmaceuticals Announces Webcast Discussion of Data to be Presented at APSS
May 24, 2017: Jazz Pharmaceuticals to Present Phase 3 Data on JZP-110, an Investigational Treatment for Excessive Sleepiness in Patients with Narcolepsy and with Obstructive Sleep Apnea, During 31st Annual SLEEP Meeting
May 17, 2017: Avadel Pharmaceuticals Supports the Narcolepsy Network's 5th Annual DREAM BIG Walk
Apr 26, 2017: Jazz Pharmaceuticals Announces Positive Results from the Phase 3 TONES 2 Study of JZP-110 in Narcolepsy Patients with Excessive Sleepiness
Apr 24, 2017: Jazz Pharmaceuticals Announces Positive Results from the Phase 2/3 EXPRESS Study of Xyrem in Pediatric Patients with Narcolepsy with Cataplexy
Mar 15, 2017: Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Study Evaluating JZP-258 for the Treatment of Cataplexy and Excessive Daytime Sleepiness in Narcolepsy
Feb 13, 2017: Lincoln Medical's Wakix Rejects For Use Within NHS Scotland
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Narcolepsy, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Narcolepsy - Pipeline by Avadel Pharmaceuticals Plc, H1 2018
Narcolepsy - Pipeline by Bioprojet SCR, H1 2018
Narcolepsy - Pipeline by Evotec AG, H1 2018
Narcolepsy - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
Narcolepsy - Pipeline by H.A.C. Pharma, H1 2018
Narcolepsy - Pipeline by Heptares Therapeutics Ltd, H1 2018
Narcolepsy - Pipeline by Jazz Pharmaceuticals Plc, H1 2018
Narcolepsy - Pipeline by Ono Pharmaceutical Co Ltd, H1 2018
Narcolepsy - Pipeline by OptiNose US Inc, H1 2018
Narcolepsy - Pipeline by Reset Therapeutics Inc, H1 2018
Narcolepsy - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2018
Narcolepsy - Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H1 2018
Narcolepsy - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018
Narcolepsy - Pipeline by Theranexus SAS, H1 2018
Narcolepsy - Dormant Projects, H1 2018
Narcolepsy - Discontinued Products, H1 2018

LIST OF FIGURES

Number of Products under Development for Narcolepsy, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

Avadel Pharmaceuticals Plc
Bioprojet SCR
Evotec AG
F. Hoffmann-La Roche Ltd
H.A.C. Pharma
Heptares Therapeutics Ltd
Jazz Pharmaceuticals Plc
Ono Pharmaceutical Co Ltd
OptiNose US Inc
Reset Therapeutics Inc
SK Biopharmaceuticals Co Ltd
Taisho Pharmaceutical Holdings Co Ltd
Takeda Pharmaceutical Co Ltd
Theranexus SAS
Skip to top


Ask Your Question

Narcolepsy - Pipeline Review, H1 2018
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: